Interviews with investors
Economy and reimbursement:
- vital importance of ROI
- high costs of patent process
- The amount of investment depends on investor’s size and profile: (from 10000 euro to couple of millions of euro).
- investment in biomarker is incomparably cheaper than investment in pharma
- pharma could go to be more interested in biomarker’s field, if they source funds from public sector (~50% of investment).
- main patent areas: U.K, Germany, France, Japan, USA. Investors nowadays consider also China and India.
- big companies are not interested in the project at early stage of development, so potential investor should be prepared to address the regulatory challenges.